GLP-1 agonists for heart disease in diabetes
Treatments studied
Part of Hormones & metabolism clinical trials.
This study is testing whether a class of diabetes medicines called GLP-1 receptor agonists can help people with type 2 diabetes and coronary artery disease. If you have recently had a heart artery-opening procedure and are already taking another diabetes medicine called an SGLT2 inhibitor, this trial may be a good fit for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 20 years old or older.
- You have type 2 diabetes and coronary artery disease.
- You had an angioplasty (a heart artery-opening procedure) within the last 3 months.
- You are currently taking an SGLT2 inhibitor (a diabetes medicine like empagliflozin or dapagliflozin).
- You have not taken a GLP-1 agonist (a diabetes medicine like liraglutide or semaglutide) in the last 3 months.
- You are not pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a type of diabetes medicine called GLP-1RA can help prevent or improve nerve damage in the heart caused by diabetes. It is for people with type 2 diabetes who are overweight or obese.
This trial tests whether a GLP-1 agonist (a type of diabetes medicine that also helps with weight loss) is safe and effective for people with spinal cord injury and type 2 diabetes who are not on other glucose-lowering drugs.
This study looks at how semaglutide (a medication for type 2 diabetes or weight management) affects your heart, kidneys, and overall metabolic health over time. It uses medical records from LMC endocrinology clinics to track real-world outcomes.
This study tests if a daily semaglutide pill can reduce harmful fat around the heart in people with type 2 diabetes who had a heart attack 2 to 9 months ago. It aims to see if this treatment can improve heart health.
This trial studies whether semaglutide can improve heart and blood-vessel outcomes in people with type 1 diabetes who use an insulin pump or automated insulin delivery. It may help reduce cardiovascular risks, but you must meet several health and medication-safety requirements.
This trial tests if combining GLP-1 and SGLT2 medications can reduce inflammation and improve heart function after a heart attack in people with type 2 diabetes and obesity. It looks for patients with a specific type of heart attack, elevated CRP levels, and preserved heart pumping ability.
Hear when a new Glucagon-Like Peptide-1 Receptor Agonists trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.